Bone Therapeutics Kicks Off ALLOB Tibial Fracture Study

Bone Therapeutics treated the first patient in the ALLOB Phase IIB clinical study treating patients with difficult-to-heal tibial fractures.

The randomized, double-blind, placebo-controlled study is examining the potential of the ALLOB allogeneic cell therapy platform vs. placebo to accelerate fracture healing and prevent late-stage...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us